103264Equipment to Support Prophylactic Antibacterial Vaccine DevelopmentClosedCentresInnovate UKAbsynth is developing vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance (AMR). Vaccines are important as prevention of infections will directly reduce the need for antibiotics. Also such prophylactic vaccines have never been shown to induce resistance. Absynth’s R&D focuses on vaccines against the infectious bacteria Staphylococcus aureus and Clostridium difficile - important to public health because of the damage and death caused by these pathogens. Absynth is able to compete against the competition because it has a suite of novel protein vaccine antigens that differ from and potentially offer benefits over competitor products. Absynth is seeking a grant to purchase equipment costing £95,000, for use in its R&D programmes. Originally Absynth leased second-hand equipment but after three years key pieces of equipment are increasingly unreliable, impacting Absynth’s ability to carry out its work. The investment is good value for money for Absynth and the taxpayer as using the new equipment the company will advance the S. aureus vaccine to the stage where the partner it has already secured, will fund preclinical safety studies and clinical trials through to market.